Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Conneqt HealthASX:CQT 3-Year EBITDA Growth Rate is 20.40% as of Dec. 2025, which is 24% above its 10-year median of 16.45. The stock has 8 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Conneqt Health ranks better than 66.09% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 0.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Conneqt Health was 43.80% per year. The lowest was -50.60% per year. And the median was 16.45% per year.
Conneqt Health (ASX:CQT) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Conneqt Health 3-Year EBITDA Growth Rate Related Terms
ASX:CQT vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Conneqt Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Conneqt Health 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Conneqt Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Conneqt Health's 3-Year EBITDA Growth Rate falls into.
Conneqt Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.40% mean?
Conneqt Health (ASX:CQT) has a 3-Year EBITDA Growth Rate of 20.40% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Conneqt Health and its competitors. This is 24% above median its historical median of 16.45. According to the industry distribution chart, Conneqt Health ranks #234 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 33.9%.
Is Conneqt Health's 3-Year EBITDA Growth Rate too high?
Conneqt Health's current 3-Year EBITDA Growth Rate of 20.40% is 24% above median its 10-year median of 16.45. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Conneqt Health's value of 20.40% is 148.8% above this industry median. Based on the distribution chart, Conneqt Health ranks #234 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Conneqt Health's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Conneqt Health ranks #234 out of 690 companies for 3-Year EBITDA Growth Rate. This puts Conneqt Health in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. Conneqt Health's value of 20.40% is 148.8% above this benchmark. While the company's 10-year median is 16.45 vs. the industry median of 8.20, Conneqt Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Conneqt Health's current 3-Year EBITDA Growth Rate of 20.40% is 148.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Conneqt Health and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Conneqt Health's current 3-Year EBITDA Growth Rate is 20.40%, which is 24% above median its own 10-year median of 16.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Conneqt Health stock overvalued right now?
Based on GuruFocus' analysis, Conneqt Health (ASX:CQT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.03, compared to a current price of A$0.02 — trading 46.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 20.40%, which is 24% above median its 10-year median of 16.45 and 148.8% above the Medical Devices & Instruments industry median of 8.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Conneqt Health (ASX:CQT), the current 3-Year EBITDA Growth Rate is 20.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Conneqt Health Ltd is a health technology company, developing solutions for health disorders. The company designs medical devices for use in cardiovascular health management. The company is mainly engaged in manufacturing biomarkers that helps to detect associated risks, optimize heart health, and empower good cardiovascular decisions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CQT has been successfully added to your 
